Motor Neuropathy Complete Antibody Panel
Use
This test supports the evaluation of suspected motor neuropathies by identifying autoantibodies associated with peripheral nervous system disorders; it helps clinicians distinguish immune-mediated motor neuropathies that are treatable from those with non-immune etiologies.
Special Instructions
Quest offers both genetic and autoimmune peripheral neuropathy testing; methodologies include cell-based assay (CBA), radioimmunoassay (RIA), and line blot as gold standards for detecting neuroautoantibodies. Specific test codes may vary by location; providers should consult the local laboratory for test code details. Serum or cerebrospinal fluid may be tested, with reflex patterns depending on initial screening by tissue immunofluorescence, line blot, and CBA.
Limitations
Interpretation may be limited when tissue immunofluorescence screening is negative and additional confirmatory testing is not reflexed; detection varies by specimen type and antibody target, and not all autoantibodies may be equally detectable in serum versus CSF. Negative results do not exclude non-autoimmune or other neuropathy etiologies.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Serum or cerebrospinal fluid (CSF) can be used for testing antigen detection via tissue immunofluorescence, line blot, and CBA.